Besides the well-known positive efficacy of tamoxifen, this study revealed a nearly statistically significant reduction in cardiovascular deaths (HR, 0.79; P = 0.08) with longer tamoxifen, and in women of 50–59 years there was an even greater reduction in cardiovascular events (HR, 0.65; P = 0.005; P = 0.046 for interaction between age and treatment groups).
In the 2012 meta-analysis trastuzumab administered for 12 months was associated with an improvement in OS [HR 0.67 (95%CI 0.57–0.80)]; although trastuzumab treatment for ⩽6 months also showed a trend towards an improvement in OS, it did not reach statistical significance [HR 0.55 (95%CI 0.27–1.11)] [160] .
The second planned interim analysis, with a median follow-up of 6 years, indicates that although trastuzumab added sequentially to CT improves DFS, there is a strong trend towards a better outcome with concurrent trastuzumab relative to sequential administration [161] .